IBM Stock Sinks as Whistleblower Case Resurfaces Despite $1 Billion Quantum Chip Factory Greenlight

IBM shares fell 4.52% after a whistleblower lawsuit over hidden cyberattacks was unsealed, offsetting gains from quantum funding and AI partnerships.

IBM shares closed at €248.15 on Friday, shedding 4.52 percent in a session that crystallised the stark contrast between the company's strategic wins and its lingering legal exposure. The slide wiped out gains from earlier in the week and left the stock 2.80 percent lower on the week, even as the broader narrative around artificial intelligence and quantum computing continued to burn bright.

The immediate trigger for the sell-off was the unsealing of a whistleblower lawsuit in a New York federal court over the weekend. William Barlow, a former vice president of threat analysis who left IBM in August 2019, accuses the company of covering up a series of major cyberattacks by the China-linked hacking group APT 10 between 2013 and 2016. According to the complaint, an internal investigation uncovered more than 56,000 potential intrusion attempts, 400 compromised accounts and 200 affected systems across 18 countries. Barlow alleges that IBM concealed these breaches from US authorities to protect billions of dollars in federal contracts. IBM has denied the allegations, insisting it has always acted in compliance with the law. The Department of Justice declined to intervene when the suit was first filed in 2020, but the renewed attention raises the prospect of formal probes or additional testimony that could weigh on the stock.

Just days earlier, however, IBM had been celebrating a very different kind of headline. The US Department of Commerce approved a $1 billion grant to build a dedicated quantum chip fabrication plant, part of a broader push to shore up domestic semiconductor production and maintain America's lead in quantum computing. The announcement reinforced the company's longstanding bet on next-generation computing architecture. IBM has also committed more than $10 billion of its own capital to quantum research over the next five years, with backing expected from the CHIPS Act. Analysts at Wedbush, Citi and Barclays maintained their positive ratings on the stock, with Wedbush and Barclays setting price targets as high as $350—roughly €323. The quarterly dividend of €1.69 per share, payable on June 10, 2026, offers a steady income stream for holders.

The quantum news came on the heels of a string of AI-related announcements that had sent the stock soaring earlier in the month. On June 1, IBM was named a partner for Nvidia's new Vera Rubin AI accelerators, a role that involves system integration, cloud services and secure storage infrastructure. The stock jumped nearly 13 percent that day, touching a 52-week high of €292.85. Then on June 4, IBM and Google Cloud unveiled a new practice designed to help enterprises scale AI projects faster, combining consulting, technical deployment and AI-powered delivery. Separately, the company kicked off its global AI Builders Challenge, giving students hands-on experience with the new IBM Bob platform, with availability set to expand to 20,000 higher-education institutions worldwide.

Despite the post-rally pullback, the technical picture remains constructive. The stock still trades 5.79 percent above its 200-day moving average of €234.58 and 17.77 percent above the 50-day average. The relative strength index stands at 60.3, signalling moderate buying interest rather than exhaustion. On a monthly basis, IBM shares have surged 29.14 percent, though year-to-date they are essentially flat at minus 0.20 percent. Over twelve months, the gain is 6.34 percent. The 30-day annualised volatility of 66 percent underscores just how turbulent trading has been.

The cooling of the stock since Monday's peak reflects not only the legal overhang but also a broader shift in market conditions. Rising oil prices, higher bond yields and shifting interest-rate expectations have pressured technology names across the board. Corporate customers, meanwhile, remain focused on cost control, which could temper the pace of AI-related deals. The next leg for IBM shares will depend on whether the partnership momentum translates into tangible revenue growth, and how regulators and courts respond to the revived whistleblower claims—a cloud that no amount of quantum funding can immediately dispel.